[go: up one dir, main page]

NO20064854L - Anvendelse av anti-CTLA-4-antistoffer - Google Patents

Anvendelse av anti-CTLA-4-antistoffer

Info

Publication number
NO20064854L
NO20064854L NO20064854A NO20064854A NO20064854L NO 20064854 L NO20064854 L NO 20064854L NO 20064854 A NO20064854 A NO 20064854A NO 20064854 A NO20064854 A NO 20064854A NO 20064854 L NO20064854 L NO 20064854L
Authority
NO
Norway
Prior art keywords
ctla
antibody
stem cell
treatment
cancer
Prior art date
Application number
NO20064854A
Other languages
English (en)
Inventor
Dennis Alan Noe
Duglas Charles Hanson
Elleen Elliott Mueller
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20064854L publication Critical patent/NO20064854L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sammendrag Oppfinnelsen angår behandling av cancer hos et pattedyr som gjennomgår stamcelletransplantasjon ved administrering av en effektiv mengde av et humant anti-CTLA-4-antistoff til pattedyret. Stamcelletransplantasjonen kan være allogeneisk eller autolog stamcelletransplantasjon og kan skje etter en forberedende behandling slik som kjemoterapi. Fremgangsmåten ifølge oppfinnelsen kan kombineres med ytterligere cancerbehandlinger. Videre angår oppfinnelse behandling av cancer ved anvendelsen av minst 10 mg/kg av et humant anti-CTLA-4-antistoff og helst ca. 15-20 mg/kg antistoff.
NO20064854A 2004-03-26 2006-10-25 Anvendelse av anti-CTLA-4-antistoffer NO20064854L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55680104P 2004-03-26 2004-03-26
PCT/IB2005/000671 WO2005092380A2 (en) 2004-03-26 2005-03-14 Uses of anti-ctla-4 antibodies

Publications (1)

Publication Number Publication Date
NO20064854L true NO20064854L (no) 2006-12-22

Family

ID=35056778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064854A NO20064854L (no) 2004-03-26 2006-10-25 Anvendelse av anti-CTLA-4-antistoffer

Country Status (15)

Country Link
US (1) US20050226875A1 (no)
EP (1) EP1732600A2 (no)
JP (1) JP2007530526A (no)
KR (1) KR100845354B1 (no)
CN (1) CN1964739A (no)
AR (1) AR049480A1 (no)
AU (1) AU2005225227A1 (no)
BR (1) BRPI0509274A (no)
CA (1) CA2560919A1 (no)
IL (1) IL177602A0 (no)
NO (1) NO20064854L (no)
RU (1) RU2346702C2 (no)
TW (2) TW200602078A (no)
WO (1) WO2005092380A2 (no)
ZA (1) ZA200607544B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074787A1 (en) * 2005-03-23 2009-03-19 Pfizer, Inc., Pfizer Products, Inc. Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
RU2007134867A (ru) * 2005-03-23 2009-04-27 Пфайзер Продактс Инк. (Us) Терапия рака предстательной железы ctla4-антителами и гормональной терапией
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010049935A1 (en) 2008-10-30 2010-05-06 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9421228B2 (en) 2008-10-30 2016-08-23 Yeda Research And Development Co. Ltd. Use of anti third party central memory T cells for anti-leukemia/lymphoma treatment
PL2769737T3 (pl) * 2009-07-20 2017-08-31 Bristol-Myers Squibb Company Kombinacja przeciwciała anty-ctla-4 z etopozydem w leczeniu synergicznym chorób proliferacyjnych
US8609092B2 (en) 2010-02-08 2013-12-17 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
EP2614083A2 (en) * 2010-09-08 2013-07-17 Yeda Research and Development Co. Ltd An immunosuppressive drug combination for a stable and long term engraftment
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
WO2013013029A1 (en) 2011-07-19 2013-01-24 The Board Of Trustees Of The University Of Illinois Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
BR112014005355B1 (pt) 2011-09-08 2022-03-29 Yeda Research An Development Co., Ltd Células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US8968742B2 (en) 2012-08-23 2015-03-03 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
CN105722534B (zh) 2013-08-01 2019-05-31 艾更斯司股份有限公司 结合cd37蛋白的抗体药物偶联物(adc)
SG11201609721WA (en) 2014-05-28 2016-12-29 Agenus Inc Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
IL251669B2 (en) 2014-10-10 2023-02-01 Idera Pharmaceuticals Inc Cancer treatment using a tlr9 agonist with checkpoint inhibitors
EP3949984A1 (en) * 2015-02-13 2022-02-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
ES2884844T3 (es) 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
DK3322425T3 (da) 2015-07-16 2023-06-12 Yeda Res & Dev Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
RU2619208C2 (ru) * 2015-10-08 2017-05-12 ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
AU2017234163B2 (en) 2016-03-15 2023-01-19 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
RU2758007C2 (ru) 2016-06-30 2021-10-25 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
CA3073984A1 (en) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
FI3710484T3 (fi) * 2017-12-20 2023-11-20 Harbour Biomed Shanghai Co Ltd CTLA-4:ää sitovia vasta-aineita ja niiden käyttöjä
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
AU2020258384A1 (en) 2019-04-15 2021-11-04 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
EP4017542A1 (en) 2019-10-04 2022-06-29 Tae Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
WO2021216920A1 (en) 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
CN117529330A (zh) 2021-06-18 2024-02-06 纳米医疗有限公司 用于治疗癌症的包括所掩蔽的I型干扰素(IFNα和IFNβ)的融合蛋白组合物和其方法
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
US20250059215A1 (en) 2023-08-07 2025-02-20 Tae Life Sciences Llc Trifluoroborate (BF3) Compositions For Use In Boron Neutron Capture Therapy and Methods Thereof
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ303703B6 (cs) * 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
IL164287A0 (en) * 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies

Also Published As

Publication number Publication date
JP2007530526A (ja) 2007-11-01
CA2560919A1 (en) 2005-10-06
IL177602A0 (en) 2006-12-10
TW200602078A (en) 2006-01-16
ZA200607544B (en) 2008-07-30
KR100845354B1 (ko) 2008-07-09
KR20070007114A (ko) 2007-01-12
AU2005225227A1 (en) 2005-10-06
TW200829271A (en) 2008-07-16
BRPI0509274A (pt) 2007-09-04
WO2005092380A2 (en) 2005-10-06
WO2005092380A3 (en) 2006-06-15
RU2346702C2 (ru) 2009-02-20
EP1732600A2 (en) 2006-12-20
RU2006134045A (ru) 2008-03-27
CN1964739A (zh) 2007-05-16
US20050226875A1 (en) 2005-10-13
AR049480A1 (es) 2006-08-09

Similar Documents

Publication Publication Date Title
NO20064854L (no) Anvendelse av anti-CTLA-4-antistoffer
You et al. Comparative analysis of periprostatic implantation and intracavernosal injection of human adipose tissue‐derived stem cells for erectile function recovery in a rat model of cavernous nerve injury
MX2009004238A (es) Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta.
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MY153573A (en) Compositions and methods of use for antibodies of dickkopf-1
WO2007084775A3 (en) Compositions and methods for modulation of suppressor t cell activation
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
WO2021087368A3 (en) Anti-cd45 antibodies and conjugates thereof
SV2006002258A (es) Inmunoterapia de trastornos autoinmunes
WO2008096268A3 (en) Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
WO2021168119A3 (en) Methods and compositions for identifying and treating subjects at risk of poor cancer survival
Ho et al. Reversal of endothelial progenitor cell dysfunction in patients with type 2 diabetes using a conditioned medium of human embryonic stem cell‐derived endothelial cells
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
Yang et al. Co‐overexpression of VEGF and GDNF in adipose‐derived stem cells optimizes therapeutic effect in neurogenic erectile dysfunction model
CA3010889A1 (en) Nucleated cell preservation by lyophilization
Xu et al. Defocused low-energy shock wave activates adipose tissue-derived stem cells in vitro via multiple signaling pathways
EA200701600A1 (ru) Способ получения лёгкодоступного клеточного материала из периферической крови и композиция на его основе
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application